Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (271 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Nippon India Index Fund - BSE Sensex |
|---|---|
| 03 Jan 2013 | ₹100.00 |
| 22 Feb 2014 | ₹105.90 |
| 13 Apr 2015 | ₹147.68 |
| 31 May 2016 | ₹136.28 |
| 20 Jul 2017 | ₹164.99 |
| 08 Sep 2018 | ₹200.39 |
| 28 Oct 2019 | ₹186.18 |
| 15 Dec 2020 | ₹203.70 |
| 03 Feb 2022 | ₹260.83 |
| 25 Mar 2023 | ₹247.79 |
| 13 May 2024 | ₹317.54 |
| 01 Jul 2025 | ₹369.80 |
| 20 Aug 2026 | ₹346.33 |
| Metric | Nippon India · Direct · IDCW NAV ₹33.53 Very High risk ★★☆☆☆ | Category median Index Funds · 271 funds |
|---|---|---|
| -4.50% | +5.06% | |
| +7.06% | +7.78% | |
| +7.17% | +8.94% | |
| +9.16% | +10.39% | |
| +9.54% | +7.54% | |
| +5.78% | — | |
| +10.28% | +8.12% | |
| +10.31% | +12.83% | |
| +10.23% | +11.97% | |
| Risk | ||
| 13.20% | 13.54% | |
| 0.04 | 0.16 | |
| 0.06 | 0.22 | |
| -43.44% | -15.77% | |
| Nifty 50 | — | |
| -0.78% | +0.53% | |
| 0.99 | 1.00 | |
| 98.5% | 102.2% | |
| 103.4% | 98.0% | |
| 0.22% | 0.34% | |
| ₹908.92Cr | ₹191.88Cr | |
| None | — | |
| None | — | |
| — | — | |
| ₹5.00K | — | |
| — | 38% | |
| Himanshu Mange | — | |
| 03 Jan 2013 | — | |
| — | — | |
| — | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.